Trial Profile
Study of CJC-1134-PC, a novel GLP-1 receptor agonist in patients with type 2 diabetes mellitus
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Mar 2015
Price :
$35
*
At a glance
- Drugs Albenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 27 Mar 2015 Study title is not official
- 05 Nov 2010 New trial record.